50 – Phase 1 Case Study & Lessons Learned (S4E5)

Welcome back, everybody. Today we're really going
to get into the nitty gritty of phase one clinical
trials. Oh, yeah. This is where the rubber meets
the road in drug development. We're going to
be using medical textbooks, FDA and ICH guidelines,
research articles, the whole shebang. We'll examine
how researchers identify and manage safety concerns,
make adjustments to those trial protocols as
they go, and ultimately figure out if a drug
is safe enough and effective enough to keep moving
forward. And it's really a dynamic process. Absolutely.
Yeah. So let's dive into a real world example.
Imagine a new drug, and this drug is meant to
treat a neurological condition. OK. We're not
going to name any specific companies or drugs,
of course. Right. But let's say this is something
that affects movement and coordination. This
phase one trial, it's focused on safety and figuring
out the right dose. Those are like the first
critical steps in figuring out how this drug
works in people. And what's really interesting
here is that they're using an oral dosage form,
basically, a pill. Interesting. And as we all
know, pills, they're not always as simple as
they seem. Oh, you're telling me. Sometimes those
things are like horse pills, you know? Right.
So true. So from that moment when you swallowed
the pill, to the drug actually making its way
to the brain where it needs to do its job. It's
a pretty amazing journey. It is a complex process.
You got to think about the drug dissolving, then
getting absorbed through the digestive system,
then it goes through the liver and gets broken
down. And finally, hopefully enough of it reaches
the brain. That's where a lot of those early
challenges can pop up in phase one trials. So
let's talk about some of those early hurdles
in this specific trial. What kind of safety signals
did they encounter? Well, when they looked at
the participants in the higher dose groups, they
saw some gastrointestinal problems cropping up.
Oh, no. Yeah, things like nausea, vomiting, you
know, the not so fun stuff. And this wasn't something
they really expected based on the preclinical
studies they had done in animals. So it was a
surprise. Kind of a curveball, yeah. And on top
of that, they noticed some litter enzyme elevations
in a few folks, which could indicate some liver
stress. Understandably, these findings definitely
raised some red flags about the drug safety profile.
So they hit some snags. Did the research team
just abandon the whole trial at that point? No,
no, not quite. They decided to temporarily pause
enrollment in those higher dose groups while
they investigated those safety signals further.
They dug deep into the data, got some expert
opinions from toxicologists and gastroenterologists,
and looked to those FDA and ICH guidelines for
guidance on how to handle situations like this.
So those guidelines are pretty crucial in these
kinds of situations, huh? Oh, absolutely. They
provide a really important framework for making
responsible, ethical decisions in drug development.
Makes sense. They stress how important it is
to monitor those safety signals carefully during
these early trials, especially when you encounter
unexpected events. And they offer some guidance
on how to adapt and change that trial protocol
to minimize the risks moving forward. It's about
finding that balance between learning as much
as we can about the drug and keeping those participants
safe. It's a tough job. So how did they end up
modifying this particular trial? to address the
safety concerns? Well, first off, they lowered
the highest dose they were testing. It's pretty
standard approach, you know, to try and reduce
how severe those side effects are. Then they
decided to monitor everyone in the trial more
closely, especially their liver function, just
to keep a really close eye on things. And lastly,
they implemented stricter criteria for who could
participate in the trial. They wanted to make
sure that anyone with pre -existing liver issues
or taking medications that might interact with
this new drug, they wouldn't be included. So
they had a multi -pronged approach, trying to
mitigate the risks from different angles. And
it really highlights how flexible and adaptable
these trial protocols can be. It's not a simple
straight line from the lab to the pharmacy. It's
a winding path, and there's constant learning
and adjustments happening all along the way.
Absolutely. Every stage, especially those early
phase one trials, can reveal new insights that
might require the researchers to reassess their
plans and adjust the course as they go. Drug
development, it's a journey of constant discovery
and refinement. Now, I know you mentioned those
FDA and ICH guidelines, and I'm curious. have
there been other cases, maybe from other phase
one trials, where researchers have run into similar
challenges and relied on those guidelines to
figure out their next steps? Absolutely, there
are tons of examples. One that comes to mind
is a trial for a new anti -cancer drug. They
encountered some unexpected cardiovascular effects
in a few of the participants. Oh, wow. Yeah,
it wasn't immediately clear why those effects
were happening, so they had to really dig deep
into the data, look into those potential mechanisms,
and consult the... regulatory guidelines to make
sure they were proceeding in the safest way possible.
So how did it play out in that case? Were they
able to continue the trial? Yes, they were able
to continue. After a very thorough review and
they consulted with cardiologists, they decided
to put in place much stricter cardiac monitoring
during the trial. They also changed the way they
were increasing the dosage, slowing down the
pace to make sure they weren't increasing it
too quickly, and they excluded anyone who already
had heart problems from participating. So by
making those adjustments, they were able to keep
learning about the drugs effects while also prioritizing
the safety of the participants. It sounds like
a tightrope walk. trying to balance that need
to move forward with the absolute priority of
protecting the people in the trial. Such a good
analogy. Because you're right, it's not just
about tweaking some numbers. It's about understanding
the science behind the drug, understanding why
those unexpected events happen, and using that
knowledge to make better decisions. It really
is a detective story. And those guidelines, like
the ones from the FDA and the ICH, act as a sort
of guidebook. They do, right? A roadmap to help
researchers navigate tricky situations. and make
those informed decisions that prioritize both
safety and scientific progress. They provide
a framework. Okay, so safety is obviously the
top priority. What other key lessons can we learn
from our case study and those real world examples
we've talked about? What are some of the big
takeaways about how phase one trials actually
work in practice? I think the most important
lesson is that managing safety signals is paramount.
Yeah. It's absolutely crucial. Researchers have
to be... They need to be on the lookout for any
unexpected events, and they need to have those
clear procedures in place for how to investigate
those signals and how to make those data -driven
adjustments to the protocol to address them.
So it's like having a really sophisticated radar
system that's constantly scanning for any blips
on the screen that can indicate a problem. Exactly.
And that radar system needs to be connected to
a team that can react swiftly and decisively.
They do, yeah, because sometimes those early
signs can be very subtle. be almost like whispers
in the data. It takes a skilled team to pick
up on those whispers and interpret them correctly.
It does. And the FDA and ICH guidelines, they
actually give researchers a blueprint for how
to build and operate that safety radar system.
They want to make sure it's as sensitive and
effective as possible. Right. So safety is paramount.
But what are some other key lessons that emerge
from this deep dive? Well, I think another really
important takeaway is that drug development,
it's an iterative process. Not always a straight
line. Definitely not a straight line. It's full
of twists and turns. Phase one trials, they're
all about learning. And sometimes the most valuable
insights come from those unexpected challenges
and those adjustments that you have to make along
the way. It's like those early explorers venturing
into uncharted territory. They set out with a
plan. but they have to be ready to adjust and
adapt based on what they find along the way.
Absolutely. Those adjustments made in phase one,
they can ripple through the entire process, it
can inform how later trials are designed, and
it can even shape what the final drug product
looks like when it actually reaches patients.
It's a continuous journey of refinement. Now,
remember that interesting tidbit we talked about
earlier about swallowing a pill? How that's not
always as simple as it seems. Oh yes, bioavailability.
That's such a great example of how even simple
things like swallowing a pill can have hidden
layers of complexity. It's true. So let's bring
it down for our listeners. What exactly is bioavailability
and why is it such a big deal in drug development?
So bioavailability is the proportion of a drug
that actually gets into your bloodstream after
you take it and the part that's actually able
to have an effect. It makes sense. It's not just
about how much drug is in that pill. It's about
how much of it actually gets to where it needs
to go in the body and how much of it is in the
right form to do its job. So it's not just about
getting it in. It's about getting it to the right
place in the right way, like sending a tiny package
on a really complicated delivery route. It's
such a good way to put it. And for pills, for
oral medications, it's kind of an obstacle course.
You have to think about that pill going through
the acidic environment of the stomach, getting
absorbed through the intestinal wall, getting
past those metabolic processes in the liver,
and finally making its way into the bloodstream
to reach its target. And at each of those steps,
there are things that can affect how much of
the drug actually gets to where it's supposed
to go. And bioavailability, that's something
that those researchers are constantly wrestling
with, right? especially in those early phase
one trials where they're trying to figure out
how much of the drug to give and how to give
it to get the desired effect without causing
harm. Absolutely. It's a key consideration in
these trials. And those regulatory guidelines,
those ones from the FDA and ICH we talked about,
offer recommendations on how to measure and evaluate
it. They stress the importance of comparing different
formulations of a drug. That way, researchers
can make sure that the one they ultimately choose
delivers the drug effectively and consistently.
Scientists are like master engineers, fine -tuning
that delivery system to ensure that the package
arrives at its destination intact and ready to
do its job. That's a perfect analogy. And that
attention to detail, especially in those early
trials, can really make the difference in whether
a drug ultimately succeeds or fails in helping
patients. Okay, so bile availability is key.
In our case study, how did the researchers actually
deal with bioavailability? Do they have to make
any adjustments based on what they learned? Remember
those gastrointestinal issues that some of the
participants experienced? Yeah. Well, those issues
could be connected to bioavailability. Really?
How so? If the pill's not releasing the drug
properly in the digestive system, you might end
up with a higher concentration of the drug in
the stomach. That can lead to irritation. That
makes sense. Or if the drug is absorbed too quickly,
it can overwhelm the liver. You know, the liver's
trying to process it all at once, and that could
lead to those elevated liver enzymes we talked
about earlier. So it's not just about the total
amount of drug. It's about when and where it's
absorbed. It's like ensuring that a package not
only arrives at the right address, but also at
the right time. Perfect analogy. So based on
what they found, those researchers started looking
into different pill formulations. They wanted
to see if they could control the release of the
drug. maybe by using a special coating or adding
some ingredients that would help it get absorbed
a little more smoothly. So they were engineering
those pills to deliver the drug in a more predictable
and targeted way, almost like those time release
capsules you see. That's a great way to think
about it. Those adjustments, all based on that
bioavailability data, could really be crucial
in ensuring the drug is both effective and safe.
It's about getting that balance right, delivering
enough of the drug to work, but not so much that
it causes problems. It's a lot to juggle. It
is. It is. You know, it's amazing what we can
learn from these early trials. It's not just
about a drug and isolation. It's about understanding
human biology. How these drugs interact with
our bodies, it's so complex. Each trial is like
a mini experiment, adding to that body of knowledge
about how to create safer and more effective
medicines in the future. And when you look at
the big picture, it's not just about getting
that drug to market as quickly as possible, it's
about getting it right. And sometimes that means
taking the time to understand the nuances. even
if you have to adjust things as you go. You've
mentioned those regulatory guidelines before,
and I know they play a huge part in those decisions
during a phase one trial, especially when safety
signals pop up. Yeah. Can you talk a little bit
about how those guidelines like the ones from
the FDA and ICH actually work in practice? Sure.
They basically provide this framework for conducting
research ethically and with scientific rigor.
You can think of them as a set of guardrails
helping researchers navigate this complex landscape
of drug development. And specifically when it
comes to managing those safety signals, these
guidelines offer a really structured approach.
It helps them identify, assess, and mitigate
the potential risks, like having a roadmap, especially
in phase one, because in phase one, you're often
seeing those effects in humans for the very first
time. So they're not just like abstract rule,
they're actually guiding those decisions in real
world trials, like the one we're talking about
today. Exactly. Remember those liver enzyme elevations
we discussed? Well, those ICH guidelines, they
directly address how to monitor and manage potential
liver injury caused by a drug. They make recommendations
about which liver function tests should be done,
how often they should be done, and the criteria
for saying, OK, we need to adjust the dose or
we need to stop the trial based on what those
tests show. So those guys headlines help those
researchers in our case study decide, how often
are we going to check those liver function tests?
And at what point do we say, OK, this is a serious
red flag, something's not right here? Exactly.
They provide that data -driven framework to make
those really crucial decisions, helping to find
that balance between learning about the drug
and keeping patients safe. And they're constantly
evolving, too. New knowledge is always coming
out, and those guidelines are updated to reflect
the most recent scientific understanding. It's
a really dynamic process. OK. That's actually
really reassuring, to know that those guidelines
are in place. like having a safety net for both
the participants and the research itself. But
it also makes you realize how complex this whole
process is. It's not just about having a brilliant
idea for a new drug. You have to think about
the science, the ethics, and all those regulations.
Oh, for sure. And it's amazing how those guidelines
try to find that balance between protecting patients
and encouraging innovation at the same time.
They give structure and guidance, but they also
allow for flexibility and adaptability. They
recognize that every drug is different and every
trial is unique. OK. Back to bioavailability
for a moment. How do those guidelines influence
how researchers approach and assess bioavailability
in a phase one trial? We know why it's important,
but how do they actually measure it? How do they
make sure enough of that drug is reaching its
target? Yeah, so bioavailability, it's definitely
a key consideration in those early trials. And
regulatory guidelines offer specific recommendations
for how to measure and evaluate it. For example,
the FDA, they emphasize doing studies to compare
different versions of a drug. different formulations.
They want to make sure that the formulation they
pick delivers the drug effectively and consistently.
And they might even compare how the drug is absorbed
when you take it orally versus intravenously,
which skips all those absorption hurdles. That
way, they can get a good idea of how much of
the drug is lost when you take it by mouth. Ah.
So it's like comparing how much water makes it
through a leaky pipe versus a direct flow. Exactly.
OK. So those guidelines would have helped the
researchers in our case study determine whether
those changes to the pill design actually improve
the bioavailability, right, like a quality control
check. Exactly. They provide that framework for
doing those comparative studies and for making
sure that data is reliable and can be used to
make decisions about how the drug is developed
moving forward. Makes sense. We've talked about
the science and the regulations, but I think
it's important not to lose sight of the human
side of things. For sure. Given all those uncertainties,
all those unexpected events, how do those ethical
considerations guide the decisions made by researchers
and regulators? Yeah, you're bringing up a really
crucial point. Ethical considerations, they are
absolutely central to every single aspect of
clinical research, but they're even more important
in phase one when we're really going into uncharted
territory. We're asking those healthy volunteers
to take on a certain level of risk. They're helping
us understand a new drug, and that's a huge responsibility.
And informed consent is the foundation. Participants
have to be fully informed about those potential
risks and benefits, understand that they can
withdraw at any time, and really feel confident
that their well -being is the top priority. So
it's not just about handing them a form to sign.
It's about a true understanding. Oh, absolutely.
It's about making sure they truly understand
what they're signing up for and that they're
making that decision freely. And informed consent
is ongoing throughout the trial. If any new information
comes up like an unexpected side effect, those
participants need to be informed and given a
chance to decide if they want to continue. It's
a constant dialogue between the researchers and
participants, all based on transparency and trust.
That makes sense. It's a partnership. Yeah. And
those ethical considerations, they go beyond
just informed consent, too, right? They influence
how the entire trial is designed and conducted.
Absolutely. Researchers have an ethical obligation
to minimize those risks to participants. They
have to carefully think about the rationale for
doing the trial in the first place, and they
have to be open about their methods and their
findings. It's all about conducting the trial
in a responsible, ethical way with the utmost
respect for those individuals who are volunteering
their time and their bodies to help us gain knowledge.
It's a good reminder that behind all of this
complexity, all the science and regulations are
real people and they trust us to do this research
the right way. Their participation is truly a
gift and we need to honor that. I couldn't agree
more. Okay. So I want to shift gears a little
bit and delve into a specific part of drug development
that often comes into play in those early trials.
And that's how the drug itself is formulated.
We've touched on this a little when we talked
about bioavailability. But I want to know more
about the work that goes on behind the scenes.
How do they turn a raw drug substance into something
someone can actually swallow? Like a pill. Formulation,
yeah. People don't always talk about it, but
it's the unsung hero of drug development. It
can have such a huge impact on a drug's success.
It's what makes sure the drug can actually be
delivered in a way that's both effective and
something someone can actually take. Exactly.
And in our case study, remember, they were trying
different ways to control the drug's release?
That's all about formulation. It's about taking
that raw ingredient, the active part of the drug,
and transforming it into that drug product that
can be safely and effectively given to patients.
So break it down for me a little bit. What exactly
is drug formulation and why does it matter so
much? Because we're talking about more than just
putting some powder into a capsule, right? Right.
It's so much more than that. It's a really complex
process. They have to pick the right inactive
ingredients, they're called excipients, to create
a stable, easy -to -use dosage form and make
sure it has good bioavailability. You can think
about it like building a delivery vehicle. You
need to choose the right materials, the right
design to make sure the cargo gets to its destination.
OK, I get it. And those delivery vehicles, they
come in lots of different forms, right? Pills,
capsules, injections, creams, inhalers. So many.
And each form has its own challenges and considerations.
In our case study, they were working with an
oral form, a pill. And one of the biggest challenges
with pills is making sure that the drug dissolves
properly once it's in your digestive system.
If it doesn't dissolve, it can't be absorbed.
The drug won't work. Another challenge is controlling
how quickly the drug is released. Some drugs
need to be released quickly and others need to
be released slowly over time for a longer lasting
effect. So it's like finding the right balance,
like is it a sprinter or a marathon rather? Exactly.
And those needs, they can be really different
depending on the drug's chemical properties,
where it needs to go in the body, and what kind
of therapeutic effect you're looking for. Some
drugs are absorbed really easily, and others
are, I'd say, notoriously finicky. So those scientists
are like detectives, figuring out how to overcome
those challenges. They are. And they have all
sorts of tools at their disposal. They can use
different coatings to control how the drug dissolves,
add things that improve absorption, and they
even use special manufacturing techniques to
create those pills with very specific release
profiles. It's constant innovation. It almost
sounds like one of those cooking shows. It does.
You know, they have to consider all those factors,
the drug's properties, how it needs to be delivered,
safety, effectiveness, and of course, what's
practical to manufacture. It's pretty amazing
how they managed to make it all come together.
It is really amazing. It's a testament to their
creativity and their dedication. They really
are pushing the boundaries. And in our case study,
those formulation adjustments, tweaking how that
pill was designed, well, those tweaks were a
big part of addressing those safety and bioavailability
challenges we talked about earlier. Right. They
were trying to make the drug release more smoothly.
So it wouldn't be so hard on the stomach. And
they wanted to assure that more of the drug actually
got to where it was needed. Exactly. OK. So I
want to bring up something that's often connected
to drug development, intellectual property, and
patents. How do those things factor into the
decisions made during a phase one trial, particularly
when it comes to how the drug is formulated?
Because we're talking about a lot of money being
invested and potential profits, right? Absolutely.
Intellectual property, it's essential for drug
development. It's what motivates companies to
invest all those resources needed to bring a
new medicine to market. And those patents are
essential for protecting those investments. And
they're like a reward for all the effort and
risk that goes into developing that drug. They
give the company exclusive rights to sell that
drug for a specific amount of time. That way
they can hopefully recoup their research and
development costs and maybe make a profit that
allows them to keep innovating. OK, so the patent
part makes sense, but how does that relate to
the formulation? They seem like two separate
things. Well, not always. Sometimes companies
develop a new formulation that's absolutely crucial
for the drug's effectiveness or safety. And that
innovation, that new formulation, can be protected
with its own patent, completely separate from
the patent on the drug itself. Oh, so it's not
just about the drug itself, but also how it's
delivered, kind of like having a secret ingredient
that makes your dish unique. That's a great way
to put it. And those formulation patents can
be really valuable. They extend the company's
exclusivity in the market and stop competitors
from just copying their product. So in our case
study, do you think any of those adjustments
they made to the formulation could be patented?
It's definitely possible. If they came up with
a totally new way to control how the drug is
released or a way to make it absorb better, that
could be protected by a patent. They're not just
scientists, they're inventors too. That's pretty
cool. It is. Okay, let's talk about how those
pills are actually made. We talked about formulation,
but what about manufacturing? How does that play
into those decisions made during a phase one
trial, especially those formulation choices?
Manufacturing is often seen as that final step,
you know, once the drug's already been developed.
But its influence actually goes all the way back
to those early trials. The formulation choices
made in phase one, they have to be scalable.
Can you make a lot of it? It's not just about
making a pill that works for a small group of
people in a trial. It's got to be something that
can be produced reliably and consistently for
potentially millions of patients. So it's like
having this great recipe at home and then figuring
out how to make it work in a huge factory. That's
exactly it. And scaling up, it can be really
challenging. You have to choose the right equipment,
get all the production steps just right, and
have really strict quality control checks at
every stage. So those manufacturing considerations
can actually shape the formulation choices back
in those early trials. They really can. If a
formulation is too complicated or it needs special
equipment that's not readily available, well,
then it might not be possible to manufacture
it on a large scale. So they're not just thinking
about what works best. in the lab, but also what's
practical to make. Exactly. It's that balance.
It is. It's a delicate dance between those two
things. OK, so it sounds like a collaborative
effort. Oh, for sure. Right. The researchers,
the people figuring out the formulation, and
the manufacturing experts, they all have to work
together to make sure that drug can actually
go from the lab to the pharmacy shelf. Exactly.
That smooth transition from discovery to delivery
is what ultimately allows us to take those breakthroughs
and make them real for patients. OK, I want to
dig a little deeper into a specific part of drug
formulation that's so crucial in those early
trials, excipients. Oh, yes, excipients. We've
mentioned them briefly, but I want to learn more.
What are they? How do they affect those early
decisions? Excipients are those unsung heroes.
They're the inactive ingredients that are mixed
with the active drug substance to create the
final product. They might not have a direct effect
themselves, but they play a huge role in making
sure that drug is safe, effective, and something
people can actually take. So they're like that
supporting cast that helps the star shine? They
are. They can do so many things. Help the drug
dissolve properly, control its release, keep
it stable, even mask its taste or add color and
texture. So with all those different jobs, choosing
the right ones must be a big part of the process.
Oh, for sure. It's a delicate balancing act.
They have to think about the drug's properties,
the form it needs to be in, and how it will be
manufactured. And just like in cooking, Using
the wrong ingredient can ruin the whole dish.
High stakes. They are. Choosing the wrong excipient
can make the drug less effective, less stable,
or even unsafe. So those choices really matter,
especially in phase one trials when you're testing
a drug in humans for the first time. You want
to be sure that those excipients aren't going
to cause any problems. Absolutely. Researchers
have to be absolutely positive that those chosen
excipients are safe. that they won't mess with
how the drug is absorbed or metabolized. And
those choices are carefully reviewed. The FDA,
for example, has really strict guidelines about
the types and amounts of excipients that can
be used in drug products. They need lots of testing
to make sure those excipients are compatible
with the drug and don't pose any safety risks.
So it's like having those food safety inspectors
checking every ingredient to make sure that final
product is safe to eat. That's a great way to
think about it. Okay, but back to our case study.
How did those adjustments to the formulation
and those excipient choices, how did those impact
the trial? Did those seemingly small changes
actually make a difference? Oh, they can make
a huge difference. Remember those gastrointestinal
side effects and those bioavailability concerns?
By modifying the formulation and being really
careful about which excipients they used, they
were able to address those issues. It's like
they were tweaking a recipe, trying out different
ingredients and methods to get that perfect balance
of effectiveness and tolerability. So fine -tuning
that delivery system, so to speak. Exactly. For
example, they might have included some excipients
that helped the drug dissolve better in the intestines
and that could reduce stomach irritation. Or
they might have used a special coating to make
the drug release slow over time, which could
help minimize side effects. So those little changes
to the pill's makeup can have a big impact on
how well it works and how safe it is. Absolutely.
And those changes often come from the data from
those early trials. It's all about constantly
learning, refining, and using what they learn
to create the best possible version of that drug.
It really shows how much goes into making a pill,
something that seems so simple. It does. It's
not just the drug itself. It's how it's delivered,
what it's made of, and how the patient experiences
it. Which brings us to something that I think
is sometimes overlooked in all the excitement
of developing a new life -changing drug. The
patient experience. How do those considerations
about the patient experience factor into the
decisions made during those phase one trials,
especially when it comes to the formulation?
Because I know those early trials are all about
safety, dosage, bioavailability, but it seems
like how the patient actually experiences the
drug is just as important. You're absolutely
right. People are recognizing more and more that
considering the patient's perspective right from
the beginning can lead to better drug products
and ultimately better outcomes. It's not just
about developing a drug that works in theory.
It's about developing a drug that patients are
actually willing and able to take. So it's about
making a user -friendly drug. Exactly. And formulation
is a big part of that. If that pill is too big,
hard to swallow, tastes terrible, patients aren't
going to take it. Even if it's the most effective
treatment out there, think about a child who
needs to take a medicine every day but refuses
because it tastes bad. Or an elderly patient
who struggles to swallow big pills. Those are
real problems that can affect how well the treatment
works. So even if you have this scientific breakthrough,
those practical challenges can prevent it from
being successful. Exactly. And that's why it's
becoming so important to get feedback from patients
during the development process, even in those
early phase one trials. So they're actually asking
those healthy volunteers about their experience
taking the drug. They are. They're using questionnaires
and interviews to find out things like, how easy
is it to swallow the pill? How does it taste?
And are you satisfied with how the drug is given?
It's almost like market research. So they're
treating those participants like partners in
the process, not just subjects in a trial. Exactly.
And that feedback is really valuable. It can
help them make decisions about the formulation.
For example, if everyone says it tastes bitter,
the researchers can look into ways to mask that
taste. If it's hard to swallow, they can try
different sizes or shapes. So little tweaks to
the pill can make a big difference in how acceptable
it is for patients. Absolutely. It's not just
about making it easier to swallow, but also about
making it more likely that people will actually
stick with their treatment. Right, because ultimately
it doesn't matter how effective a drug is if
people aren't actually taking it. Exactly. Patient
adherence is crucial. A drug sitting unused on
a shelf doesn't help anyone. So it sounds like
those scientists are advocates for the patients,
trying to create medicines that work well and
are easy to take. I think that's a great way
to put it. And that patient -centric approach
is becoming more and more important. The goal
is to improve people's lives, not just create
new molecules in the lab. OK, let's go back to
our case study one more time. Do you think any
of the changes they made to the formulation were
based on feedback from the participants? It's
definitely a possibility. Remember those gastrointestinal
side effects? Well, if those participants were
saying that the drug was causing discomfort or
nausea, the researchers might have tried to find
a different formulation that was easier on the
stomach. So those patient experiences could have
directly led to a better, more tolerable pill.
It's like they were responding to customer feedback.
Exactly. And that customer -centric approach
is becoming really important in drug development.
It's recognizing that the goal is to create medicines
that people actually want to take. Now, I want
to talk about something that's often a big challenge,
especially for people who have ever tried to
swallow a bad tasting pill. Taste masking. Oh,
yeah. Why is that so important? And how does
that play into those decisions during a phase
one trial? Taste masking is crucial, especially
for anything you take by mouth. So many drugs,
they just taste awful naturally. Bitter, metallic,
just unpleasant. And if a pill tastes bad, people
aren't going to want to take it. And that can
have a huge impact on how well their treatment
works. Like that saying, a spoonful of sugar
helps the medicine go down. But it's more than
just making it taste good. It's about making
sure people will actually take the medicine they
need. That's exactly it. And that's where those
scientists have to get creative. They have to
find ways to disguise that unpleasant taste.
It's like they're culinary magicians, making
something that tastes bad into something people
can actually tolerate. So how do they do it?
What are some of the tricks? They have all sorts
of techniques. They can add flavors to mask the
bitterness, coatings to prevent the drug from
hitting your taste buds directly, even sweeteners
to make it more palatable. It's all about creating
a disguise. So they have to find that sweet spot.
where it's both effective and something people
can actually swallow. Exactly, and that often
involves a lot of experimenting. They'll do taste
tests with trained panels and also get feedback
from real patients, because taste is subjective,
so you need to know what real people think. So
they're using some of the same strategies as
those food and beverage companies, doing focus
groups and taste tests to make sure people like
it. Yeah, that feedback is really important.
If everyone hates a certain flavor, they can
try something else. It's all about making the
medication as easy to take as possible. OK, back
to our case study. Do you think taste masking
might have been part of those formulation adjustments?
It's definitely possible. If the drug had a bad
taste, those participants would have said something.
And that feedback might have led the researchers
to try some different taste masking techniques,
maybe adding flavorings, coatings, or sweeteners.
they were listening to those customers, so to
speak, and trying to make a product that they
would actually like. Exactly. And that customer
-centric approach, it's becoming more and more
important in drug development. The goal is to
make medicines that are both effective and enjoyable
to take. So we've talked about a lot of factors,
but I want to bring up something that often gets
overshadowed by the excitement of a new, possibly
life -changing drug. Cost. Ah, yes, cost. How
do those cost considerations, the reality of
how expensive drug development is, how do those
things affect the decisions made during a phase
one trial, especially when it comes to the formulation?
Cost is huge. It can really impact the choices
made early on. Developing a new drug is so expensive,
and a lot of those costs end up being passed
on to patients in the form of high drug prices.
So it's like walking a tightrope. You're trying
to create an effective and innovative drug, but
you also want to make sure that it's affordable.
It's a constant balancing act, and that's often
reflected in the formulation decisions made during
those early trials. Those researchers and companies
have to think about the cost of all those ingredients,
the excipients, the manufacturing processes,
and even the packaging. So it's not just about
the science, it's also about the business side
of things. Exactly, and those commercial considerations
can lead to some tough choices. For example,
a more complex formulation might make the drug
work better, but it might also be more expensive
to make. Right, so they have to weigh those potential
benefits against the cost. They do. And these
conversations about cost, they need to happen
early on, not just when the drug is about to
go on the market. Absolutely. Ignoring those
cost considerations until the end can cause delays,
price increases, and even mean that promising
treatments never make it to patients. So those
phase one trials are about more than just testing
a drug. They're about building a sustainable
health care system. That's a great way to put
it. We need a health care system that balances
innovation with affordability. OK, one more time
back to our case study. Do you think cost played
a role in those adjustments they made to the
formulation? It's very possible. If a certain
ingredient or process was really expensive, they
might have looked for alternatives. Maybe they
chose a formulation that wasn't quite as sophisticated,
but that meant the drug would be more affordable.
It's all about those strategic decisions. It
is. I want to bring up something that I think
is really important. but doesn't always get the
attention it deserves, the environmental impact
of drug manufacturing. Yeah, that's a really
important point. How do those considerations
affect the choices made during a phase one trial,
especially when it comes to the formulation?
Well, the pharmaceutical industry, like any other,
has an impact on the environment, and there's
definitely increasing pressure to reduce that
impact. So it's not just about creating effective
medicines, it's about doing it responsibly. Exactly.
Thinking about the planet as well as the patients.
And that responsibility extends to those formulation
decisions made early on. Those scientists are
starting to consider the environmental effects
of different ingredients, manufacturing processes,
and even packaging. It's about looking at the
whole life cycle of the drug. That's interesting.
What are some of the specific environmental concerns?
Well, one major concern is the use of hazardous
chemicals in manufacturing. Some of those ingredients
and solvents can be toxic or they can persist
in the environment, posing a risk to wildlife
and even people. So it's about finding safer
alternatives. Exactly. There's a lot of research
going on right now into greener manufacturing
processes, using fewer hazardous chemicals, creating
less waste, and saving energy. People are demanding
products that are both effective and environmentally
friendly, and the pharmaceutical industry is
starting to listen. Back to our case study. Do
you think those environmental considerations
might have played a part in their formulation
decisions? It's definitely possible. If a certain
ingredient or process was known to be harmful
to the environment, they might have chosen a
different, more eco -friendly option, even if
it meant a slightly higher cost or a slightly
less sophisticated design. It's about making
those choices that benefit both people and the
planet. Absolutely. Okay, let's talk about another
really important piece of the puzzle. Regulatory
strategy. We've discussed the FDA and ICH guidelines,
but there's a whole world of regulations that
can affect drug development. How do those considerations
shape the choices made during a phase one trial?
especially when it comes to formulation. Regulatory
strategy is so important. It's like playing chess.
You have to think several moves ahead to be successful.
Because those regulations can be pretty tricky.
They can. And those considerations, those regulations,
need to be part of the plan from the very beginning.
So it's not just about making a drug that works.
It's about making a drug that meets all those
FDA requirements. You got it. And those requirements,
they can influence everything from how the trial
is designed to the ingredients and how the drug
is manufactured. It's a balancing act between
scientific progress and following the rules.
So those early trials aren't just about testing
the drug. They're also about getting all the
data needed to get approval later on. That's
right. Having a good regulatory strategy can
save you a lot of time and money. It helps make
sure the whole process goes smoothly and efficiently.
Can you give us some examples of how those regulatory
considerations might affect the formulation decisions?
Sure. One thing that comes to mind is the choice
of excipients. Those inactive ingredients. Right.
Those regulatory agencies, they have really specific
guidelines about which excipients you can use
and how much you can use. And they require a
lot of testing to make sure they're safe and
that they work well with the drug. So those scientists
have to be really careful about what they put
in those pills. They do. And sometimes those
regulations can actually limit their options.
There might be a certain ingredient that would
make the drug work better, but maybe the FDA
is concerned about its safety, so they have to
find something else. So it's a team effort, getting
those scientists, the regulatory experts, and
even the lawyers involved. It definitely is.
Back to our case study. Do you think those regulatory
considerations play a role in those formulation
adjustments? Most likely, yes. They would have
been thinking about those FDA guidelines when
they were choosing those ingredients and figuring
out the manufacturing process. They wouldn't
want to do anything that could cause problems
later on when they're trying to get the drug
approved. So they're not just scientists. They're
strategists, too. Exactly. And that strategic
thinking is so important in drug development.
It can really help speed up the process of getting
new treatments to patients. Yeah, it really does.
It takes a lot of foresight and planning. It
does. I want to shift gears a little bit and
talk about something that's sometimes overlooked
in those early stages of drug development, commercial
viability. Okay. We talked about safety, we've
talked about effectiveness, we've talked about
regulations, but at the end of the day, These
companies are businesses, right? They are. They
need to make sure that those drugs they're developing
have a shot at being successful out there in
the marketplace. That's right. Commercial viability
is the ultimate test for any new drug. No matter
how amazing a treatment might be, if it's not
commercially viable, it's probably not going
to reach the patients who need it. So these companies
aren't just doing research, they're running businesses.
And they need to make a profit so they can fund
more research and development. Exactly, and that
need to make a profit, it can really impact the
decisions that are made throughout the whole
process, even those related to the formulation.
So those scientists, they're not just thinking
about the science, they're also thinking about
the market. They are. They have to understand
how many patients might need the drug, what other
treatments are already out there, and how they're
going to price it. all of those factors. They
have to think about all of it. And those commercial
considerations, they can definitely influence
the formulation choices they make. So can you
give us some specific examples of how those commercial
considerations might affect those decisions about
formulation? Sure. Let's say a company is developing
a drug for a rare disease. OK. The number of
patients who might need that drug could be pretty
small, which means the drug's commercial potential
might be limited. Makes sense. In that situation,
the company might choose a simpler, less expensive
formulation, even if it's a little bit less effective
or doesn't have quite as good bioavailability.
They're trying to balance creating a treatment
that works with making sure it's actually feasible
to bring it to market. So it's about weighing
those potential benefits against those financial
realities. Exactly. It's a tricky balance for
sure. And those commercial considerations can
also affect decisions about things like taste
masking, the packaging, even the drug's name.
They're trying to make a product that will stand
out, get noticed, and that will ultimately benefit
both the company and the patients. So those early
phase one trials, they're not just about exploring
the science. They're also about setting the stage
for a successful launch. Absolutely. And that
commercial perspective, it's becoming more and
more important. The days of just developing drugs
because they're scientifically interesting, those
days are pretty much over. So those scientists
have to be business minded as well as brilliant
researchers. That's right. Now, let's bring it
back to our case study one last time. Do you
think those commercial considerations played
a role in those formulation adjustments they
made? Probably, yeah. They would have been thinking
about the potential market for the drug. Were
there other drugs already out there to treat
this condition? If so, they might have tried
to develop a formulation that offered something
extra, maybe better bioavailability, a more convenient
dosing schedule, or even just a better taste.
So they were thinking about the marketing as
well as the science. Yeah, exactly. Trying to
give their drug the best shot at success. And
those strategic decisions, the ones made early
on, they can make all the difference. This deep
dive has been fascinating. It has. We've covered
so much from the molecules themselves to the
marketplace. All the different factors that go
into creating a new drug. So many pieces of the
puzzle. It's not just about discovery. It's about
safety, regulations, patient needs, commercial
viability, and so much more. It's a complex process,
but it's also incredibly exciting. pushing the
boundaries of what's possible to create treatments
that can really make a difference in people's
lives. So what does all this mean for the future
of drug development? What are the key things
our listeners should keep in mind? Well, I think
one of the biggest takeaways is that drug development
has to be a holistic endeavor. We can't just
focus on the science in isolation. We have to
consider all those interconnected factors, the
safety, the ethical considerations, the regulations,
the patient needs, the commercial aspects, all
of it right from the start. It's like they're
conducting a symphony, all these different parts
working together. That's a great analogy, and
that's so crucial for developing medicines that
are both groundbreaking and actually available
to the people who need them. Another key takeaway
is adaptability. Our case study shows that unexpected
things can happen at any point and we have to
be ready to adjust our approach. Like navigating
a ship through uncharted waters. Exactly. You
need a plan, but you also have to be ready to
change course when the winds shift. So the key
is to have a good strategy, but also be flexible.
That's right. That balance is essential. Now,
before we wrap up, I want to leave our listeners
with something to think about. Given all the
complexities we've talked about today, the ethical
concerns, the scientific challenges, the regulatory
hurdles, what do you think is the most important
ingredient in developing a successful drug? That's
a tough one. There's no easy answer. But I think
one crucial ingredient is often overlooked. Collaboration.
Teamwork. Exactly. Drug development is no longer
a solitary endeavor. You need scientists, doctors,
regulators, manufacturing experts, marketing
people, and most importantly, patients all working
together. Like weaving a tapestry. Yes, bringing
all those different threads of knowledge and
experience together. And that tapestry, when
it's created with care and collaboration, it
can become something truly beautiful and beneficial
for everyone. That's a great way to put it. Well,
expert speaker, Thank you so much for joining
us on this deep dive into phase one clinical
trials. It's been incredibly insightful. It's
been my pleasure. I always love talking about
drug development. It's such a fascinating process.
And to our listeners, thank you for tuning in.
We've only scratched the surface of this topic.
So if you're interested in learning more, check
out the show notes for links to the sources we
discussed and some other resources. And remember,
every pill you take, every medicine that helps
you feel better, it represents a triumph of human
ingenuity, collaboration, and perseverance. That's
right. And until next time, stay curious, keep
learning, and remember. The world of drug development
is full of surprises, challenges and the potential
to truly make a difference in the world.